Roivant (ROIV-Q)
NASDAQ:ROIV
11.03
0.14
(1.25%) 1d
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
This summary was created by AI, based on 5 opinions in the last 12 months.
Roivant (ROIV) continues to be positioned favorably among analysts, highlighted as a TOP PICK multiple times by Michael O'Reilly. Analysts have noted the company's strong fundamentals, including robust cash reserves and a growing return on equity (ROE), while also emphasizing the importance of careful risk management with recommended stop-loss levels. Despite a recent decline in stock price, the company is viewed positively due to its promising pipeline in biopharma, particularly in treatments for autoimmune disorders and pulmonary hypertension. With a current trading valuation at about 2x earnings and book value, and its anticipated joining of the S&P MidCap 400, the outlook remains optimistic, with potential upsides ranging from 27% to 33% noted across different reviews. Nevertheless, disciplined investment strategies are suggested, particularly with varying price targets from analysts, showing a spectrum of expectations for the stock's future performance.
We again reiterate ROIV as a TOP PICK. The Swiss based biopharma company continues to develop its long pipeline of projects. It trades at 2x earnings, under 2x book and supports a robust 128% ROE. We like that cash reserves are growing, while debt is retired. We continue to recommend a stop-loss at $10.50, looking to achieve $16 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $16.25)We reiterate ROIV as a TOP PICK. The pharma company has continued to increase R&D spending into drugs for treatment such as autoimmune issues respiratory hypertension. It trades at 2x trailing earnings and 1.6x book value, while supporting a robust return on equity. We like that cash reserves are growing, while debt is retired. We recommend maintaining the stop at $10.50, looking to achieve $15.00 -- upside potential of 27%. Yield 0%
(Analysts’ price target is $17.06)After announcing positive reports in two important autoimmune drugs, we again reiterate ROIV as a TOP PICK. It trades at 2x earnings, under 2x book and supports a robust return on equity. We like that cash reserves are growing, while debt is retired. We recommend trailing up the stop (from $9:50) to $10.50, looking to achieve $16.00 -- upside potential of 28%. Yield 0%
(Analysts’ price target is $17.06)As this $9 billion market cap pharma company will join the S&P MidCap 400, we reiterate ROIV as a TOP PICK. Cash reserves are growing and the company trades at 1.5x book. We recommend trailing up the stop (from $7.50) to $9.50, looking to achieve $15 -- upside potential of 33%. Yield 0%
(Analysts’ price target is $15.90)The pharma company recently received supportive results for its new product which helps bring relief to patients with eye inflammation and pain and can help avoid total blindness -- steroids are presently the primarily treatment currently. It trades at 2x trailing earnings and 1.4x book value. The board has approved a $1.2 billion share buyback, which it has ample and growing cash reserves to manage. Recently reported revenues beat expectations, growing by 118% from the year previous and is expected to grow by 50% p.a. for at least the next five years. We recommend setting a stop-loss at $7.50, looking to achieve $16.00. Yield 0%
(Analysts’ price target is $16.08)- «
- ‹
- 1
- ›
- »
Roivant(ROIV-Q) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 1
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 1
Roivant(ROIV-Q) Frequently Asked Questions
What is Roivant stock symbol?
Roivant is a American stock, trading under the symbol ROIV-Q on the NASDAQ (ROIV). It is usually referred to as NASDAQ:ROIV or ROIV-Q
Is Roivant a buy or a sell?
In the last year, 1 stock analyst published opinions about ROIV-Q. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Roivant.
Is Roivant a good investment or a top pick?
Roivant was recommended as a Top Pick by on . Read the latest stock experts ratings for Roivant.
Why is Roivant stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Roivant worth watching?
1 stock analyst on Stockchase covered Roivant In the last year. It is a trending stock that is worth watching.
What is Roivant stock price?
On 2025-05-08, Roivant (ROIV-Q) stock closed at a price of $11.03.
Our PAST TOP PICK with ROIV has triggered its stop at $10.50. To remain disciplined, we recommend covering the position at this time. This will result in a net investment loss of 9%, when combined with our previous guidance.